CASI Pharmaceuticals (CASIF) Asset Utilization Ratio (2024 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Asset Utilization Ratio came in at 0.83 in Q4 2025, up 69.88% YoY from 0.49 in Q4 2024, and down 14.3% on a QoQ basis from 0.96 in Q3 2025.
CASI Pharmaceuticals (CASIF) Asset Utilization Ratio (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 2 years of Asset Utilization Ratio data on file, last reported at 0.83 in Q4 2025.
- Quarterly Asset Utilization Ratio rose 69.88% year-over-year to 0.83 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.83 (up 69.88% YoY) and the FY2025 annual result came in at 0.52, up 17.98% from the prior year.
- Asset Utilization Ratio slipped to 0.83 in Q4 2025, from 0.96 in the prior quarter.
- In the past five years, Asset Utilization Ratio ranged from a high of 2.02 in Q2 2025 to a low of 0.43 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.47 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.38 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 0.20 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.69 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.90 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.13 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.54 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.13 |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.83 |
| Sep 30, 2025 | 0.96 |
| Jun 30, 2025 | 2.02 |
| Mar 31, 2025 | 1.17 |
| Dec 31, 2024 | 0.49 |
| Sep 30, 2024 | 0.69 |
| Jun 30, 2024 | 0.80 |
| Mar 31, 2024 | 0.43 |